Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 18, 2022

View Archived Issues

Novel cdkl5-mutated zebrafish model of CDKL5 deficiency disorder

Insulin is tissue-specific, with link to weight complex

Purdue Research Foundation patents protein kinase inhibitors

Universite de Franche-Comte presents compounds targeting histamine H3 receptors

TCR-modified T cells targeting TdT show antileukemia promise in vivo

SCN5A tied to drug-induced cardiac arrythmia

PEGylated circularly permuted capsule depolymerase enzyme protects mice from anthrax infection

VelociT mouse model for analyzing T-cell function in human disease

Ono and Neurimmune expand drug discovery collaboration for neurodegenerative diseases

EZH2 as a promising therapeutic target for prostate cancer

MCC-1381, a pan-HDAC inhibitor with promising anticancer activity

ZIP8 found to correlate with severe rheumatoid arthritis

4basebio and eTheRNA collaborate to evaluate linear DNA for mRNA production

Avacta selects FAP-targeted proteasome inhibitor for preclinical development

SUW-133 diminishes HIV viral load in vivo

Researchers suggest ZEB2 targeting as an approach for atherosclerosis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...